Thoracic Oncologist, Chief of Heme/Onc @Georgetown @MedStarGUH, Head of Developmental Therapeutics @LombardiCancer, #DCLung26 #TexasLung27 #HereWeGo #LetsGoBucs
Georgetown, Washington, DC
- Tweets 23,432
- Following 3,635
- Followers 30,605
- Likes 111,223
Pinned Tweet
Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a 1-day, comprehensive, @IASLC endorsed, multidisciplinary, discussion-based lung cancer CME update! From trainee to seasoned professional, MD to RN, local or not - something for everyone!
medstarhealth.org/dclung
3
10
47
7,795
Phase II study of 3G ALK TKI ficonalkib (SY-3505) at #WCLC26 showed in pts with prior 2G ALK TKI therapy, RR 43% (66/153), DOR 15.2m, PFS 9.7m, 1y OS rate 79%. No neurologic toxicity. Most common TRAEs were GI (diarrhea, nausea). 1L phase III study ongoing.
1
1
90
Early insights into resistance to HER2 TKIs in NSCLC emerged at #WCLC26. Zongertinib & sevabertinib now both approved as 1L+ treatment for advanced NSCLC with a HER2 TKD mt. While efficacy similar, these are distinct agents and we need to learn how to leverage those differences.
1
6
27
1,304
In Beamion LUNG-1 with zongertinib, 8 paired tissue results from pts with PD showed two acquired HER2 mutations: T862A and S783C. Notably absent were T798I (gatekeeper) and C805S (binding site). The acquired mutations not detected in plasma. #WCLC26 @dplanchard
1
2
9
416
In SOHO-01 with sevabertinib, much larger dataset from @LeXiuning @PrelajArsela. In 73 pts with paired evaluable ctDNA (HER2+ at baseline), 22 had a putative resistance event. T862A seen in 16% with one compound T798I/T862A. HER2 amplification seen in 3%. No C805S and no S783C.
6
305
Stephen V Liu, MD retweeted
Daiichi Sankyo and Merck withdraw the BLA application for I-DXd in ES-SCLC!
2
9
42
4,458
Beware honors, titles, and accolades from sham organizations!
SCOOP: Top researchers at Columbia, Stanford, and others thought they were elected to elite scientific societies alongside Nobel laureates. The catch? The organizations are a sham.
I spent the last month investigating a massive academic scam, for @Nature
nature.com/articles/d41586-0…
1
1
7
2,243
An unfortunate development in a SCLC landscape where post-tarlatamab, few approved options. Would not read too much into the withdrawal - need to wait for phase III results as phase II likely inadequate. The B7-H3 class holds great promise with tam-peli, ris-rez, & I-DXd.
Quite a surprise, I-dxd BLA application withdrawn. The wait for an ADC for small cell lung cancer outside China will continue, disappointing news #lcsm stocktitan.net/news/MRK/ifin…
2
6
48
3,330
Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a one-day, comprehensive, multidisciplinary, discussion-based lung cancer CME update! Dr. @NaglaAKarimMD joins as faculty to discuss the latest advances in treating EGFR mutant NSCLC!
medstarhealth.org/dclung
8
826
Stephen V Liu, MD retweeted
What does @chulkimMD of @MedStarHealth think are the most impactful studies presented at #WCLC26? on this #HealthcareUnfiltered EXPRESS, Dr. Kim summarizes what you need to know in 16 minutes.
From Maverick to ADAURA and more.
Check it out - streaming everywhere.
1
7
17
2,024
Stephen V Liu, MD retweeted
Today is World Cancer Research Day, and the perfect opportunity to support @lombardiCancer's @RideBellRinger as we ride 25, 50, or 100 miles on October 23-24, 2026. Funds raised support vital research at Georgetown's Lombardi Comprehensive Cancer Center. #GearUpEndCancer. Learn more: bit.ly/RueschBellRinger.
2
6
416
Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a one-day, comprehensive, multidisciplinary, discussion-based lung cancer CME update! Nurse Practitioner Jennifer Wheeley adds to the discussion on managing immunotherapy in NSCLC!
medstarhealth.org/dclung
1
5
1,019
Stephen V Liu, MD retweeted
Acknowledgment of Reviewers 2026.
Read the full article. bit.ly/3UNkscJ
1
4
6
11,724
Stephen V Liu, MD retweeted
Today, an @FDA advisory panel voted 7–2, with 1 abstention, that the benefits of @GrailBio Galleri multi-cancer early detection (MCED) test outweigh its risks. A closely watched milestone for the field.
And if you haven’t seen it yet, the NHS-Galleri randomized trial was published yesterday in @NEJM:
nejm.org/doi/abs/10.1056/NEJ…
3
26
96
13,018
Updates in 9/2026 NCCN NSCLC Guidelines: sevabertinib as 1L option for HER2 mt NSCLC & daraxonrasib (off label at 200mg daily dosing) added to consider in pts with KRAS mutant NSCLC. In phase I/II, post chemo-IO, RR ~ 42%, DOR ~1y. Worth pursuing if no access to clinical trials.
4
13
60
13,464
Stephen V Liu, MD retweeted
It was a privilege to be part of the 13th OncoWisdom discussion, What’s New in Lung Cancer from WCLC 2026?
My appreciation to Dr Amol Akhade for the opportunity and for an engaging discussion with several new perspectives.
9 take-home messages that stayed with me:
• Bullish on ivonescimab
• The appetite for PCI is shrinking
• The next decade belongs to SCLC
• Rethinking thoracic RT in the era of newer therapies
• ctDNA/MRD after 3 years of adjuvant osimertinib
• Lessons from EVOKE-03
• The increasingly impressive ROS1 TKI space
• Impressive T-DXd PFS in HER2-mutant NSCLC
• Exon 20ins is heterogeneous — where the insertion sits matters
@SuyogCancer
@StephenVLiu
@LauraAlderMD
@TejasPatilMD
@g_mountzios
@ullas_batra
@karansood
#LungCancer #ThoracicOncology #MVOnco
2
21
45
2,589
Update from SOLARA trial of BH-30643, a macrocyclic, mutant-selective, CNS penetrant EGFR TKI at #WCLC26. In EGFR C797S, RR 45% (18/40) with DCR 88% and 63% of pts still on therapy. Low discontinuation from TRAE (3%) with only 1% pneumonitis. Has fast-track designation from FDA.
1
8
27
3,358
Rapid fire discussion on #WCLC26 with global oncology colleagues Drs. @LauraAlderMD @TejasPatilMD @ChandrakanthMv @QuantumOnc @ullas_batra @g_mountzios led by @SuyogCancer - always appreciate the different perspectives everyone brings to the emerging data.
7
34
3,125
Early results from REACH-EGFR trial of VRN110755, a mutant selective EGFR TKI, at #WCLC26 show activity in EGFR C797S (6/6 responses) with ctDNA clearance and early signs of intracranial efficacy. Most common TRAE was rash but no discontinuations due to TRAE in 67 pts.
9
22
2,220